The FDA on November 8, 2023, approved FRUZAQLA® (Fruquintinib) for adult patients with metastatic ColoRectal Cancer (mCRC) who received prior Fluoropyrimidine, Oxaliplatin, and Irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA® is a product of Takeda Pharmaceuticals, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
